Early in my career as a pediatrician, I would sometimes lie
awake at night worrying about pneumococcus. Pneumococcus
is a type of strep bacteria (different than the one that causes strep throat) which
can cause serious infections such as meningitis, bloodstream infections, and
pneumonia. Unfortunately, early in the course of an invasive pneumococcal
infection, the symptoms can be the same as in a plethora of common,
self-limited, viral infections, especially in young children.
This is what resulted in sleepless nights, wondering if I
could have missed something serious hidden among the multitude of benign
illnesses. As a result, we would obtain labs on some children with fevers who
met certain criteria or even admit them to the hospital
for observation or give them injections of antibiotics until we had final blood
culture results available, usually in 48 hours. Most of those children did not
end up having serious illnesses but, depending on the situation, waiting to see
could have resulted in what are sometimes referred to euphemistically as “bad
outcomes.”
The first pneumococcal conjugate vaccine was introduced in
2000 and there was a 76% decrease in invasive pneumococcal infections over the
next seven years. In 2010, a new version of the vaccine containing more serotypes
of pneumococcal antigens was released. A new study in JAMA Pediatrics reports a further 70% decrease in invasive
pneumococcal disease in a population of children in New York City monitored since
the introduction of the new vaccine.
I can’t remember the last time I saw an invasive
pneumococcal infection. I sleep much better than I used to. And most importantly, children and their families are at much lower
risk of these serious infections than they used to be.